UNICREDIT BANK/CALL/BIOGEN IDEC/450/0.1/17.12.25 | Real-time Bid/Ask 17:54:48 21/05/2024 BST | ||
| 0.63 EUR / 0.68 EUR | -3.68% |
|
| Current month | +83.78% | ||
| 1 month | +631.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 21/05/24 | 0.63 | -7.35% |
| 20/05/24 | 0.68 | -10.53% |
| 17/05/24 | 0.76 | 0.00% |
| 16/05/24 | 0.76 | -1.30% |
| 15/05/24 | 0.77 | +22.22% |
Delayed Quote Börse Stuttgart
Last update May 21, 2024 at 07:26 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD1H9P |
| ISIN | DE000HD1H9P4 |
| Date issued | 28/12/2023 |
| Strike | 450 $ |
| Maturity | 17/12/2025 (575 Days) |
| Parity | 10 : 1 |
| Emission price | 1.5 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.47 € |
|---|---|
| Lowest since issue | 0.011 € |
| Spread | 0.05 € |
| Spread % | 7.25% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
231.6
USD
Average target price
285.9
USD
Spread / Average Target
+23.47%
- Stock Market
- Warrants
- Warrant
